A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients

por Shore, Neal, Mincik, Ivan, DeGuenther, Mark, Student, Vladimir, Jievaltas, Mindaugas, Patockova, Jitka, Simpson, Kelle, Hu, Chu-Hsuan, Huang, Shih-Tsung, Li, Yuhua, Lee, Yisheng, Chien, Ben, Mao, John
Publicado 2019